+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

Visiongain Publishes Precision Medicine Market Report 2022-2032

05 July 2022
Pharma

Visiongain has published a new report entitled Precision Medicine Market Report 2022-2032: Forecasts by Product Type (Diagnostics (Genetic Tests, Biomarker-based Tests, Others), Therapeutics), by Application (Oncology, CNS, Immunology, Respiratory, Others), by End-user (Hospitals, Diagnostic Centres, Research & Academic Institutes, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

The global precision medicine market was valued at US$63,333 million in 2021 and is projected to grow at a CAGR of 10.8% during the forecast period 2022-2032.

Accelerated Demand for Targeted Therapy
According to a 2016 survey published in an article by the National Centre for Biotechnology Information (NCBI), 75% of physicians believe that genomic testing could improve the treatment of cancer patients. The article further stated that the US annually spends $5 billion on genetic tests, which is anticipated to reach $15-25 billion by 2021 further accelerating the targeted therapy demand. Growing awareness about the benefits of personalized medicine is also one of the key factors in the upsurge of precision medicine, genomics & proteomics technologies. Precision medicine which involves the analysis or specific indications for specific drugs in a particular patient, are an essential part of individualized treatment regimens for many chronic diseases and conditions. Implementation of patient-selection diagnostic set-up in the earlier phases of drug development has been the core objective of pharmacological, pharmaceutical and biopharmaceutical firms for which significant efforts are being put so that targeted therapies are delivered to the right candidate which further supplements the growth of the precision medicine market. For instance, Roche has developed EGFR inhibitor Osimertinib sold under the brand name “Tagrisso” for treating lungs cancer and monoclonal antibody trastuzumab sold under the brand name “Herceptin” for HER-2. Genentech had launch BRAF inhibitor vemurafenib commercially known as “Zelboraf”, and Merck has come up with immunotherapy pembrolizumab sold as “Keytruda” which targets the exact biomarkers regardless of tumour location. Other FDA approved therapies in rare and advance cancer includes Novartis’s “Kymriah” and Gilead’s “Yescarta”. These therapies enable healthcare providers to make informed clinical decisions and reduce the likelihood of unnecessary adverse events.

How has COVID-19 had a significant impact on the Precision Medicine Market?
The COVID-19 disruption has handicapped the global market extensively due to numerous challenges in supply chain of lot of essentials. The European Union has been revamping its guidelines on precision medicine, to bring them in line with internationally established standards. However, these political priorities might get impacted due to the COVID-19 pandemic not only for current year but also in future. In Europe, scrutiny has been on the conflicts amongst Member States’ own actions and those taken mutually at European Union level. The initial indications of nationalist political response of member states, such as the closing of borders and export bans on medical equipment were not encouraging.

Moreover, during the pandemic, termination of elective care to increase hospital capacity and social distancing measures to reduce community spread of the coronavirus resulted in a steep drop in healthcare use and expenditure. This has certainly delayed and hindered surgeries and testing on biopsy tissue. Thus, delayed biopsies, postponed preventative screening and medical appointments might lead to wave of more advanced cancers since earlier the cancer is detected, the better the outcome.

However, as the year progressed, healthcare use and spending began to rebound as in-person care resumed for hospital and lab services. Thus, the challenges also give birth to opportunities, and it is rightly applied to the healthcare care industry which is now living through the impact of the COVID-19 pandemic and evolving under changing circumstances. Precision medicine treatments can help to increase the positive patient outcome for severely affected COVID patients. There are more than 60 subtypes of SARS-CoV-2; all patients have complex array of underlying risk and disease tolerance; and all patients have varying response towards COVID-19. These aspects help to promote the use of personalized treatment based on the requirement of the patient. Thus, COVID has helped promote the importance of precision medicine for treatment of different diseases.

How will this Report Benefit you?
Visiongain’s 435-page report provides 267 tables and 411 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global precision medicine market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for precision medicine. Get financial analysis of the overall market and different segments including product type, application, end user, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing precision medicine market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Growing precedence of precision medicine over traditional practice of “one-size-fits-all” therapies
At present most of the diagnostic test are being carried out in centralized, hospital-based or clinical laboratories which makes use of expensive equipment and highly trained professionals. The costly, time-consuming, and invasive nature of these tests makes it extremely challenging for healthcare professionals to diagnose diseases in the early stage a key issue faced by healthcare systems across the globe. This, however, has led to the development of fast, reliable, and disease specific diagnostic tools that can be used to eliminate the traditional practice of “one-size-fits-all” therapies and help in determining a specific therapy for patients, which reduces overall healthcare costs and improve public health. Precision medicine reduces healthcare costs by decreasing the consumption of reagents, shortening analysis times, and increase efficiency. Precision medicine not only helps in early detection and screening of chronic diseases but also improve patient outcomes by providing high diagnostic accuracy and most-effective targeted therapy options. Recent advances in precision medicine technologies integrated with non-invasive procedures are accelerating the development of rapid, low-cost, and reliable diagnostics and therapeutics. Many new technologies and tests are also being developed that integrate the various functions of sample collection, analytic deduction, and readout. These advantages of precision medicine and increasing test marketing of these therapies are expected to drive market growth in the coming years.

Increase in scope of application of precision medicine
Precision medicine approach can be used to assess and treat have various application areas such as immunology, respiratory disorders, oncology, central nervous system (CNS), and other diseases. Currently oncology is the major application area of precision medicine. Various diagnostic tests and therapeutics have been developed for breast, lung, and colorectal cancer. Several studies are exploring the possibilities of developing diagnostic tests and therapeutics for other cancer indications, such as prostate cancer, ovarian cancer, and leukaemia. New entrants have identified this opportunity to venture into the market by developing tests for rare indications, such as ovarian cancer. The applications of precision medicine are also increasing in the domain of genetic diseases. This approach is being increasingly used for rare disease genetic tests, cardiovascular genomics, and in the field of neurogenetics. Precision medicine is also being increasingly used to screen genetic risk for hereditary disease, non-invasive prenatal testing, and pharmacogenomics. Several drug manufacturers are also focusing on the development of precision medicine for neurological diseases, such as Alzheimer's and Parkinson's disease. For instance, Roche Diagnostics developing a biomarker for Alzheimer's disease. Takeda Pharmaceuticals and AstraZeneca are also investigating biomarkers for Alzheimer`s disease and asthma. At present, oncology offers significant market potential as this segment requires precision medicine for better treatment options. Technologies such as NGS and liquid biopsy are widely adopted for this purpose, with companies such as Illumina and Thermo Fisher scientific partnering with pharmaceutical companies to develop NGS based diagnostic tests for precision medicine. However, as the avenues for the use of precision medicine grow, they will present potential growth opportunities for other non-oncology stakeholders in the market.

Where are the Market Opportunities?

Growing Use of AI in Healthcare
Over the decade, biotechnology has progressed immensely. Computers are becoming faster in speed and micro in size, heterogeneity is increasing in datasets and their volume is growing robustly. These developments are fuelling the engine of artificial intelligence in medical science and thus finds a huge opportunity in precision medicine. Technological progressions through AI are transforming the medical industry by assisting healthcare professional’s record clinical data and monitor it on a regular basis, with greater ease and fewer errors. For example, in 2018, researchers at the Seoul National University Hospital and College of Medicine developed a Deep Learning-Based Automatic Detection (DLAD) which is an AI algorithm, to inspect chest radiographs and identify abnormal cell growth, such as potential cancers. Also, in August 2020, Renalytix AI plc and AstraZeneca plc partnered to launch strategies for precision medicine for cardiovascular, renal, and metabolic diseases. Thus, the increasing usage of AI in precision medicine will boost the market growth. Artificial intelligence and deep networks are changing the approach to medical bioinformatics at an unparalleled speed. As a result, the decision-making processes in precision medicine will shift from an algorithm-centric to a data-centric insight. Further advancement in pattern recognition and image processing will allow synergies between AI technology and modern pathology which will lead to more accurate drug response prediction and prognosis of this underlying disease. Thus, the convergence of artificial intelligence (AI) and precision medicine is anticipated to revolutionize health care industry.

Competitive Landscape
The major players operating in the precision medicine market are Pfizer Inc. Group Ltd., Qiagen Inc., Quest Diagnostics Inc., Illumina, Agilent Technologies, Novartis AG Inc., BioMérieux SA Industries AG, Abbott Laboratories International GmbH, F Hoffmann-La Roche AG, Eli Lilly & Company, GlaxoSmithKline Plc, AstraZeneca plc Corporation, Thermo Fisher Scientific, Inc., Myriad Genetics Inc., and Abnova Corporation. These major players have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.

Recent Developments
• In March 2022, Pfizer entered into clinical trial collaboration with IDEAYA Biosciences to evaluate darovasertib and crizotinib combination therapy to treat metastatic uveal melanoma and hepatocellular carcinoma.
• In February 2022, Eli Lilly announced the establishment of Institute for Genetic Medicine with an investment of $700 Million in Boston Seaport Site as a part of the company's strategy to advance RNA based therapeutics.
• In December 2021, Roche launched the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Contract Research Organisations (CROs) Market Report 2022-2032

The global Contract Research Organizations (CROs) market was valued at US$57.1 billion in 2021 and is projected to grow at a CAGR of 9.95% during the forecast period 2022-2032.

12 August 2022

Read

Visiongain Publishes Genome Editing Technologies Market Report 2022-2032

The Global Genome Editing Technologies market is estimated to be valued at US$ 4,225.48 million in 2022. The market is projected to reach a market value of US$ 18,570.41 million by 2032. We predict strong revenue growth through to 2032.

02 August 2022

Read

Visiongain Publishes Synthetic Biology Market Report 2022-2032

The global synthetic biology market was valued at US$13.8 billion in 2021 and is projected to grow at a CAGR of 25.52% during the forecast period 2022-2032.

27 July 2022

Read

Visiongain Publishes Biosimilar Monoclonal Antibodies Market Report 2022-2032

The global biosimilar monoclonal antibodies market was valued at US$4,087 million in 2021 and is projected to grow at a CAGR of 23.5% during the forecast period 2022-2032.

25 July 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever